GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (MEX:SOBI N) » Definitions » Cyclically Adjusted Revenue per Share

Swedish Orphan Biovitrum AB (MEX:SOBI N) Cyclically Adjusted Revenue per Share : MXN93.69 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted revenue per share for the three months ended in Mar. 2025 was MXN37.619. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN93.69 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Swedish Orphan Biovitrum AB's average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 22.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Swedish Orphan Biovitrum AB was 25.90% per year. The lowest was 22.30% per year. And the median was 23.70% per year.

As of today (2025-06-30), Swedish Orphan Biovitrum AB's current stock price is MXN523.55284. Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN93.69. Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is 5.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.24.


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 80.22 91.15 85.04 82.54

Swedish Orphan Biovitrum AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.21 85.75 76.82 82.54 93.69

Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio falls into.


;
;

Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=37.619/132.8245*132.8245
=37.619

Current CPI (Mar. 2025) = 132.8245.

Swedish Orphan Biovitrum AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.187 99.995 6.890
201509 5.667 100.228 7.510
201512 5.880 100.276 7.789
201603 9.312 100.751 12.276
201606 11.609 101.019 15.264
201609 9.423 101.138 12.375
201612 10.266 102.022 13.366
201703 10.442 102.022 13.595
201706 12.074 102.752 15.608
201709 12.836 103.279 16.508
201712 15.495 103.793 19.829
201803 15.299 103.962 19.546
201806 18.027 104.875 22.831
201809 17.098 105.679 21.490
201812 19.738 105.912 24.754
201903 22.504 105.886 28.229
201906 20.875 106.742 25.976
201909 19.233 107.214 23.827
201912 31.515 107.766 38.843
202003 35.522 106.563 44.276
202006 24.477 107.498 30.244
202009 23.792 107.635 29.360
202012 34.789 108.296 42.669
202103 28.008 108.360 34.332
202106 24.563 108.928 29.952
202109 28.806 110.338 34.676
202112 35.463 112.486 41.875
202203 32.918 114.825 38.078
202206 24.909 118.384 27.947
202209 23.210 122.296 25.208
202212 36.496 126.365 38.362
202303 28.763 127.042 30.072
202306 24.708 129.407 25.361
202309 25.474 130.224 25.983
202312 33.030 131.912 33.259
202403 28.984 132.205 29.120
202406 27.576 132.716 27.599
202409 38.261 132.304 38.411
202412 40.678 132.987 40.628
202503 37.619 132.825 37.619

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Swedish Orphan Biovitrum AB  (MEX:SOBI N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=523.55284/93.69
=5.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines